Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-16

Clinical Trial Update: Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing safety and efficacy of dexmedetomidine for sedation in pediatric patients undergoing MRI shows completed results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: Pfizer | Conditions: MRI Sedation | Phase 4 | Status: COMPLETED | Results posted: 2022-11-16